52934-83-5 Usage
Description
NANAOMYCIN A is a pyranonaphthoquinone antibiotic derived from the strain OS-3966 of Streptomyces rosa var. notoensis. It is a type of secondary metabolite produced by certain bacteria, which exhibits antimicrobial properties.
Uses
Used in Pharmaceutical Industry:
NANAOMYCIN A is used as an antibiotic for treating bacterial infections. Its potent antimicrobial activity makes it a valuable compound in the development of new drugs to combat resistant bacteria.
Used in Research and Development:
NANAOMYCIN A serves as a crucial compound in the field of microbiology and pharmaceutical research. It is utilized for studying the mechanisms of antibiotic action, resistance, and the development of novel antimicrobial agents.
Used in Agricultural Industry:
In agriculture, NANAOMYCIN A can be employed as a biopesticide to control bacterial diseases in crops, thereby improving crop yield and reducing the reliance on chemical pesticides.
Biological Activity
nanaomycin a is a selective inhibitor of dna methyltransferase 3b (dnmt3b) with ic50 value of 500 nm [1].in the biochemical in vitro methylation assay, nanaomycin a showed selective inhibition of dnmt3b but not dnmt1 although it was docked to the catalytic domain of human dnmt1 in a multi-step docking approach. nanaomycin a showed cell viability inhibition in hct116, a549 and hl60 cells with ic50 values of 400 nm, 4100 nm and 800 nm, respectively. it decreased the genomic methylation level of these cells significantly. besides that, nanaomycin a treatment resulted in demethylation of the rassf1a promoter in a549 cells. the demethylation caused by nanaomycin a reactivated the transcription and expression of a silenced tumor suppressor gene [1].
references
[1] kuck d, caulfield t, lyko f, et al. nanaomycin a selectively inhibits dnmt3b and reactivates silenced tumor suppressor genes in human cancer cells. molecular cancer therapeutics, 2010, 9(11): 3015-3023.
Check Digit Verification of cas no
The CAS Registry Mumber 52934-83-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,2,9,3 and 4 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 52934-83:
(7*5)+(6*2)+(5*9)+(4*3)+(3*4)+(2*8)+(1*3)=135
135 % 10 = 5
So 52934-83-5 is a valid CAS Registry Number.
InChI:InChI=1/C16H14O6/c1-7-13-10(5-8(22-7)6-12(18)19)15(20)9-3-2-4-11(17)14(9)16(13)21/h2-4,7-8,17H,5-6H2,1H3,(H,18,19)/t7-,8+/m0/s1
52934-83-5Relevant articles and documents
Unveiling Two Consecutive Hydroxylations: Mechanisms of Aromatic Hydroxylations Catalyzed by Flavin-Dependent Monooxygenases for the Biosynthesis of Actinorhodin and Related Antibiotics
Hashimoto, Makoto,Taguchi, Takaaki,Ishikawa, Kazuki,Mori, Ryuichiro,Hotta, Akari,Watari, Susumu,Katakawa, Kazuaki,Kumamoto, Takuya,Okamoto, Susumu,Ichinose, Koji
, p. 623 - 627 (2019/12/15)
Flavin-dependent monooxygenases are ubiquitous in living systems and are classified into single- or two-component systems. Actinorhodin, produced by Streptomyces coelicolor, is a representative polycyclic polyketide that is hydroxylated through the action of the two-component ActVA-5/ActVB hydroxylase system. These homologous systems are widely distributed in bacteria, but their reaction mechanisms remain unclear. This in vitro investigation has provided chemical proof of two consecutive hydroxylations via hydroxynaphthalene intermediates involved in actinorhodin biosynthesis. The ActVA-5 oxygenase component catalyzed a stepwise dihydroxylation of the substrate, whereas the ActVB flavin reductase not only supplied a reduced cofactor, but also regulated the quinone–hydroquinone interconversion of an intermediate. Our study provides clues for understanding the general biosynthetic mechanisms of highly functionalized aromatic natural products with structural diversity.
Enantiodivergent total syntheses of nanaomycins and their enantiomers, kalafungins
Tatsuta,Akimoto,Annaka,et al.
, p. 1699 - 1706 (2007/10/02)
The first, enantiospecific total syntheses of pyranonaphthoquinone antibiotics, nanaomycins D and A, and their enantiomers kalafungin and 4-deoxykalafunginic acid, are described by an 'enantiodivergent' strategy from a common optically active intermediate, (1S,3RS,4S)-3,4-dihydro-5,9,10-trimethoxy-1-methyl-1H-naphtho[2,3-c]pyr an-3,4-diol, which has been derived from L-rhamnose via condensation of 4-methoxy-3-(phenylsulfonyl)-1-(3H)-isobenzofuranone and methyl 3,4,6-trideoxy-α-L-glycero-hex-3-enopyranosid-2-ulose.